Oncoradio Centre Oncogard — Clinical Trial Site

27 Registered trials

12 Currently recruiting

Organisation

Oncoradio Centre Oncogard

Location

Nimes Cedex 9, France

Identifier

ORG-100047899

Address

Rue Du Professeur Henri Pujol Institut De Cancerologie, 30029, France

Departments

2316 Oncology Medical
Centre médicale ONCOGARD
Clinical Hematology
Department of Medical Oncology
FR30002 Hematologie clinique
Hematology
Medical oncology
Medical Oncology Department
Oncologie
Oncologie médicale
oncology
Oncology Department
Service Hématologie Clinique
Service Hématologie Clinique et Oncologie Médicale

Clinical trials at this site (27)

Search interface

MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy… Pending

2024-516576-15-00 metastatic breast cancer 10
Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending

2024-519624-24-00 HER3-mutant and HER2-not amplified metastatic breast ca 4
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla… Recruiting

2024-511003-42-00 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS 4 2025-12-11
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Metastatic Castration-Resistant Prostate Cancer 5 2025-06-23
ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2024-512043-22-00 Metastatic prostate cancer 4 2025-04-11
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting

2023-506282-66-00 Women with ER+ HER2- metastatic breast cancer who progr 5 2024-05-27
Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma… Recruiting

2024-512827-36-00 Penis carcinoma 4 2016-10-17
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab… Ended

2024-511650-50-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-01-17
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended

2023-507468-38-00 Myelofibrosis 4 2022-04-22
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06